IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 141 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 0.41 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $283,718 | +36.4% | 46,435 | +936.3% | 0.02% | +240.0% |
| Q4 2020 | $208,000 | -35.6% | 4,481 | -54.3% | 0.01% | -68.8% |
| Q3 2020 | $323,000 | +0.9% | 9,806 | -15.9% | 0.02% | -11.1% |
| Q2 2020 | $320,000 | +32.2% | 11,658 | +43.9% | 0.02% | +12.5% |
| Q1 2020 | $242,000 | -40.8% | 8,099 | -45.2% | 0.02% | 0.0% |
| Q4 2019 | $409,000 | +53.2% | 14,768 | +0.5% | 0.02% | +33.3% |
| Q3 2019 | $267,000 | +8800.0% | 14,693 | +9083.1% | 0.01% | – |
| Q2 2019 | $3,000 | -95.2% | 160 | -97.1% | 0.00% | -100.0% |
| Q3 2018 | $62,000 | -55.7% | 5,500 | -50.0% | 0.00% | -50.0% |
| Q2 2018 | $140,000 | -38.6% | 11,000 | -18.5% | 0.01% | -52.9% |
| Q1 2018 | $228,000 | +185.0% | 13,500 | +35.0% | 0.02% | +183.3% |
| Q4 2017 | $80,000 | +37.9% | 10,000 | +33.3% | 0.01% | +20.0% |
| Q3 2017 | $58,000 | -80.1% | 7,500 | -81.0% | 0.01% | -82.1% |
| Q2 2017 | $291,000 | – | 39,534 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 2,222,701 | $25,005,000 | 8.92% |
| Broadfin Capital, LLC | 4,894,361 | $55,062,000 | 8.10% |
| GREAT POINT PARTNERS LLC | 3,496,340 | $39,334,000 | 6.13% |
| FRAZIER MANAGEMENT LLC | 2,188,331 | $24,619,000 | 4.51% |
| Prosight Management, LP | 715,317 | $8,047,000 | 4.49% |
| Avoro Capital Advisors LLC | 8,662,720 | $97,456,000 | 4.48% |
| QVT Financial LP | 821,361 | $8,748,000 | 2.26% |
| Perceptive Advisors | 7,290,199 | $82,014,000 | 2.19% |
| Rhenman & Partners Asset Management AB | 1,290,495 | $14,518,000 | 1.46% |
| EMORY UNIVERSITY | 185,915 | $2,092,000 | 1.37% |